Pravastatin

In adults with hypercholesterolemia but without diabetes at baseline, pravastatin treatment over several years did not significantly worsen fasting glucose or insulin levels and was not associated with a major increase in new-onset diabetes compared with usual care, suggesting a relatively neutral effect on glycemic control in this population.

This review of randomized controlled trials in adults found that 40 mg of pravastatin daily reduced total cholesterol by about 25–34% and was associated with roughly a 24% reduction in death from cardiovascular diseases, with a favorable overall safety profile in primary and secondary prevention populations.

This review of randomized controlled trials in adults found that 40 mg of pravastatin daily reduced total cholesterol by about 25–34% and was associated with roughly a 24% reduction in death from cardiovascular diseases, with a favorable overall safety profile in primary and secondary prevention populations.

In 70–82-year-old men and women at risk of vascular disease, pravastatin 40 mg daily lowered LDL cholesterol by about 34% and reduced the composite endpoint of coronary death, nonfatal myocardial infarction, and fatal or nonfatal stroke compared with placebo over a mean follow-up of 3.2 years, without major safety concerns in generally stable participants.

In adults with primary hypercholesterolemia but no overt cardiovascular disease, pravastatin therapy significantly improved endothelium-dependent vasodilation in the brachial artery along with reductions in LDL cholesterol, indicating improved vascular function in otherwise stable subjects.

In 70–82-year-old men and women at risk of vascular disease, pravastatin 40 mg daily lowered LDL cholesterol by about 34% and reduced the composite endpoint of coronary death, nonfatal myocardial infarction, and fatal or nonfatal stroke compared with placebo over a mean follow-up of 3.2 years, without major safety concerns in generally stable participants.

In healthy, physically active adults without cardiovascular disease, short-term pravastatin use was associated with mild increases in muscle-related symptoms and small changes in creatine kinase, without significant impairment in overall exercise tolerance or cardiorespiratory fitness.

A pooled analysis of multiple trials in adults with primary hypercholesterolemia showed that pravastatin had an overall incidence of adverse events similar to placebo, with mild gastrointestinal complaints, headache, and muscle symptoms among the most frequently reported events and very low rates of serious liver or muscle toxicity.

A pooled analysis of multiple trials in adults with primary hypercholesterolemia showed that pravastatin had an overall incidence of adverse events similar to placebo, with mild gastrointestinal complaints, headache, and muscle symptoms among the most frequently reported events and very low rates of serious liver or muscle toxicity.

A pooled analysis of multiple trials in adults with primary hypercholesterolemia showed that pravastatin had an overall incidence of adverse events similar to placebo, with mild gastrointestinal complaints, headache, and muscle symptoms among the most frequently reported events and very low rates of serious liver or muscle toxicity.

A pooled analysis of multiple trials in adults with primary hypercholesterolemia showed that pravastatin had an overall incidence of adverse events similar to placebo, with mild gastrointestinal complaints, headache, and muscle symptoms among the most frequently reported events and very low rates of serious liver or muscle toxicity.